ELV Stock Forecast & Price Target

Elevance Health is favored because it is demonstrating earnings durability, with 3Q26 results beating expectations and management raising FY26 adjusted EPS guidance to at least $29.00 while also reaffirming at least 12% EPS growth in 2027. Its outlook is strengthened by improving Medicaid trends, where margins are now seen as slightly better than prior guidance and 2026 is framed as a trough before 2027 recovery, alongside better-than-expected Individual ACA retention and stronger Medicare Advantage margin progression above 2%. The company’s long-term appeal is also supported by Carelon’s growing contribution, with CarelonRx operating gain up 10.8% year over year, plus a differentiated Blue Cross Blue Shield footprint and integrated services model that can drive profitable share gains and sustained cash generation.

Elevance Health is under pressure from multiple fundamental headwinds, led by approximately $669 million of liabilities tied to Independent Dispute Resolution matters and another $324 million of unresolved exposures, with about 94% linked to ASO business and ongoing uncertainty from regulation and litigation. Its earnings mix is also vulnerable because IngenioRx contributes about 20% of total company earnings, while Medicare Advantage, Medicaid, and ACA markets face reimbursement cuts, redetermination-driven deterioration, and adverse selection risk that could weaken pricing and margins. Even with Carelon and value-based care expansion, management has lowered target operating margins to 5.0-6.0%, signaling that elevated medical cost trends, integration risk, and government-program volatility may keep financial performance under sustained pressure.